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Two articles published this year described the clinical and pathologic aspects of cases of acute lymphoid and acute myeloid leukemia in the horse. 2, 3 The article from this issue 3 represents the largest collection of complete cases describing the clinical signs, laboratory findings, diagnostic investigations, and biological behavior. Leukemia in the horse is uncommonly recognized, being less frequent than lymphoma, so the large number of cases is critical to the understanding of acute equine leukemia. Leukemia is defined by the presence of neoplastic cells in blood and/or bone marrow. Acute leukemia is currently defined by 20% blast cells of the total nucleated cell population in the bone marrow. Blast cells are recognized by a high nuclear:cytoplasmic ratio, round to oval nucleus with finely dispersed chromatin or abundant euchromatin, and 1 nucleoli. These immature cells are increased in the bone marrow and may circulate in the blood. Aspirate biopsies of the bone marrow provide cytologic details of the cell population, which help to identify cell lineage and dysplastic changes. Surgical biopsies or necropsy samples provide valuable information about the degree of neoplastic involvement and are best to evaluate megakaryocyte numbers and changes in stromal architecture. The clinical presentations of the 2 case series were very similar, with signs such as lethargy, anorexia, and fever of short duration, usually <2 weeks in young horses (median age, up to 3.6 years). These series both displayed evidence of concurrent inflammation with hyperfibrinogenemia or increased concentrations of acute phase proteins in all cases, hypoalbuminemia in two-thirds of cases, and lymphadenopathy in about half the cases. However, in 1 case series, half the leukemic cases displayed limb or ventral edema and bleeding episodes, which differed from the infrequent evidence of these signs in the other series. 2, 3 Hematologic data were very similar, with moderate anemia and marked neutropenia and thrombocytopenia. Leukocytosis was not a feature of acute leukemia in these horses. Biological behavior of these hematolymphatic conditions indicated a progressive disease with short duration of the illness until euthanization occurred within days to weeks of the diagnosis. Although most horses were euthanized following the lack of response to supportive care or attempted immunosuppressive therapy, most bone marrows were not completely effaced by neoplastic cells, which suggests that myelophthisis is not responsible for the multiple cytopenias. It is more likely that inflammatory cytokines or an altered marrow environment reduces differentiation of blast cells and precursor cells, many of which are poorly functional. A significant difference between the case series was the presence of left-shifted neutrophils with toxic change in 1 study, which suggested bone marrow damage; however, this finding was not supported in the current study, as toxicity was rarely noted, a finding that agrees with other reports of equine leukemia. [1] [2] [3] [4] [5] [6] The rapid release of maturing neutrophils that results in toxicity is typically related to infectious or toxic insults to the bone marrow, but under some conditions, leukemia (especially with severe neutropenia) may result in a similar finding.
Once the diagnosis of acute primary leukemia is supported by blood and bone marrow evaluation with the lack of a primary tissue neoplasm, lineage should be determined. Unless there is obvious differentiation of the cells, morphologic appearance is not reliable to determine cell of origin. A good example of this difficulty is another 2017 publication, involving a case of B-cell lymphoma in a horse with numerous circulating pleomorphic cells that morphologically resembled myelomonocytic cells. 5 The highly clefted or cerebriform nuclei posed a diagnostic challenge regarding cell lineage, for which was immunochemistry was performed. The case also highlighted the limited number of antibodies validated for use in equine cases. Cooper et al attempted to validate additional immunomarkers for the acute myeloid leukemia cases by using several antibodies for myeloperoxidase and CD34 with variable dilutions on control canine and equine specimens. 3 This study expanded knowledge about the use of less commonly used antibodies, such as CD163, CD172a, and Iba-1, as helpful indicators of myeloid origin. An earlier publication was successful in using a validated equine granulocytic marker (CD13) to support the diagnosis of acute myelogenous (granulocytic) leukemia. 4 The current study exclusively used immunohistochemistry to distinguish myeloid and lymphoid leukemias, except to evaluate peroxidase activity (via a hematology analyzer). 3 This allowed use of archival material rather than fresh specimens. In contrast, a previous study combined cytochemistry and immunochemistry, the latter through flow cytometry and immunohistochemistry for analysis. 2 With fresh samples, cytochemical staining can help to determine granulocytic and monocytic origins for the poorly differentiated blast cells (Figs. 1, 2a, respectively) . Cytochemistry is a helpful addition to the battery of diagnostic tests for cell lineage, as it remains inexpensive and simple to perform. As demonstrated in an earlier publication, the diagnosis of acute myeloid (granulocytic) leukemia was made only through cytochemical stains, such as peroxidase, Sudan black B, chloroacetate esterase, alkaline phosphatase, acid phosphatase, and alpha naphthyl acetate esterase. 6 Similarly, a case of acute equine monocytic leukemia was diagnosed by positive monocytic and negative granulocytic cytochemical markers (Fig. 2b) . 1 Biphenotypic expression of immunologic markers in 2 cases of acute myeloid leukemia were attributed to aberrant expression of T-cell genes, adding to the dilemma in using immunochemistry as the sole diagnostic tool in horses. 2 Lymphoid leukemia cases were easily identified and phenotyped, with the exception of 1 case. 3 Since the degree of immunoreactivity was identified by the percentage of positively stained blast cells, the phenotype was determined by the larger proportion of reactive cells. In another study, lymphoid immunomarkers were not always definitive, as flow cytometry suggested 1 phenotype but immunohistochemistry suggested another. 2 Neither of the recent studies used immunocytochemistry, which can best identify the cell morphology of the neoplastic and reactive cell populations. The use of immunocytochemistry should have been considered, as several antibodies work best on fresh or frozen tissue samples. The 1 lymphoid leukemic case that was unclassified as either B or T could have been further evaluated by molecular analysis to determine which population was clonal and which was reactive, as previously demonstrated in a case report. 3, 5 Note that a panel of B and T immunomarkers is better than single lineagespecific markers. Furthermore, some cell types require >1 antibody for identification; for example, CD20 and CD79a are often used concurrently to identify B-cell lineage. This was apparent in a case in which flow cytometry demonstrated a difference among antibodies used to indicate the B-cell origin. 5 In this case, an antibody to a membranous antigen (CD21) was negative, while an antibody to a transmembrane antigen (CD79b) reacted with a majority of neoplastic cells. Emphasis should be on broad panels for myeloid and lymphoid lineage determination. By limiting antibodies to only myeloid leukemia cases, the Iba-1 antibody-a mostly macrophage marker-could not be investigated for lymphoid leukemia cases. 3 In contrast, 2 of 3 lymphoid leukemia cases in 1 study demonstrated reactivity with the antibody to Iba-1, which suggests that Iba-1 may not be as specific for macrophages as initially considered. 2 In summary, when fresh samples are available, more information can be learned through flow cytometry, immunocytochemistry, and cytochemistry, followed by immunohistochemistry and clonality assays when necessary. However, the current study provided a strong foundation and model for additional studies of equine hematolymphatic disease from archived materials. 
